Aktis Oncology Started Phase 1b BActinium-2 Trial
The Boston-based company launched a new clinical trial for its radioconjugate therapy targeting B7-H3 expressing tumors.
Updated on Oct. 1, 2026 in Cancer
Live Poll
Do you feel optimistic about the current pace of research into targeted cancer radiopharmaceuticals?
Aktis Oncology has initiated the BActinium-2 clinical trial, a multicenter, open-label study evaluating the radioconjugate AKY-2519. This new trial explores three different dose levels in patients diagnosed with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors.
Why it matters
This trial represents a broader effort to expand the application of AKY-2519 across multiple cancer types. The initiative aims to determine the safety and efficacy of the treatment as the company advances its clinical pipeline.
The BActinium-2 trial is a multicenter, open-label clinical study evaluating three distinct dose levels of the therapeutic radioconjugate AKY-2519. The protocol allows for the expansion of enrollment at specific dose levels once preliminary findings are gathered.
The players
Aktis Oncology
This Boston-based biotechnology company focuses on developing novel radioconjugate therapies for the treatment of various cancer types.
The details
The Boston-based firm is simultaneously moving forward with its BActinium-1 trial for metastatic castration-resistant prostate cancer (mCRPC). The current study is designed to broaden the potential therapeutic range of AKY-2519 for patients with various B7-H3 expressing tumors.
Timeline
May 2026: Aktis Oncology initiated the BActinium-1 trial and presented ASCO clinical imaging data.
October 1, 2026: The BActinium-2 trial was officially initiated.
Q1 2027: Preliminary data for the NECTINIUM-2 trial is expected to be released.
2027: Preliminary data for the BActinium-1 trial is expected.
The Big Picture
This study follows the established pattern of prioritizing B7-H3 expressing tumors as a viable target for next-generation radioconjugate therapies. The move reflects a broader industry shift toward highly targeted radiation treatments that minimize exposure to healthy tissues.
This trial provides an additional clinical pathway for patients with NSCLC and other specific tumors who meet the study criteria. Enrollment eligibility depends on the presence of B7-H3 protein expression, a requirement that will be confirmed through standard diagnostic testing.
The takeaway
The initiation of the BActinium-2 trial marks a significant step in the clinical development of AKY-2519. Patients and healthcare providers should monitor future data releases in 2027 to assess how these trials impact potential future treatment options.
Further reading
For more information on the current landscape of oncology research, visit the Cancer section.
More information
To learn more about the company's research, visit the Aktis Oncology corporate website.
Live Poll
Do you feel optimistic about the current pace of research into targeted cancer radiopharmaceuticals?
